Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 191-200 of 271 for Lung cancer

Edit search filters
  1. Study Of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily And In Combination With Dabrafenib Twice Daily And Trametinib Once Daily In Combination Therapy In Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  2. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Jacksonville, FL, Rochester, MN

  3. A Study To Evaluate Adverse Events And Change In Disease Activity Of Intravenous ABBV-706 Versus Standard Of Care In Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    Jacksonville, FL, Rochester, MN

  4. A Study Of APR-246 And Pembrolizumab In Patients With Solid Tumor Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. JAB-3312 Based Combination Therapy In Adult Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Study Of TJ011133 In Participants With Relapsed/ Refractory Advanced Solid Tumors And Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study Of MCLA-128 In Patients With Solid Tumors Harboring An NRG1 Fusion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy In Early-Stage Resectable NSCLC (VIGOR)

    Rochester, MN

  9. Neoadjuvant Pembrolizumab

    Rochester, MN

  10. Safety Study Of Enoblituzumab (MGA271) In Combination With Pembrolizumab In Refractory Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer